PNC Financial Services Group Inc. Has $38,000 Holdings in Dova Pharmaceuticals Inc (DOVA)

PNC Financial Services Group Inc. raised its position in shares of Dova Pharmaceuticals Inc (NASDAQ:DOVA) by 14,705.9% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 5,034 shares of the company’s stock after buying an additional 5,000 shares during the period. PNC Financial Services Group Inc.’s holdings in Dova Pharmaceuticals were worth $38,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently made changes to their positions in the business. Rhumbline Advisers lifted its position in shares of Dova Pharmaceuticals by 46.1% in the 4th quarter. Rhumbline Advisers now owns 15,343 shares of the company’s stock worth $116,000 after purchasing an additional 4,843 shares during the period. Stonepine Capital Management LLC purchased a new stake in shares of Dova Pharmaceuticals in the 3rd quarter worth about $145,000. Tower Research Capital LLC TRC purchased a new stake in shares of Dova Pharmaceuticals in the 3rd quarter worth about $158,000. Dynamic Technology Lab Private Ltd purchased a new stake in shares of Dova Pharmaceuticals in the 3rd quarter worth about $242,000. Finally, Russell Investments Group Ltd. purchased a new stake in shares of Dova Pharmaceuticals in the 3rd quarter worth about $267,000. 30.09% of the stock is owned by institutional investors and hedge funds.

Shares of Dova Pharmaceuticals stock opened at $8.90 on Tuesday. The company has a debt-to-equity ratio of 0.18, a current ratio of 5.73 and a quick ratio of 5.51. The stock has a market capitalization of $251.25 million, a P/E ratio of -3.42 and a beta of 2.06. Dova Pharmaceuticals Inc has a 1 year low of $5.62 and a 1 year high of $35.33.

Dova Pharmaceuticals (NASDAQ:DOVA) last issued its quarterly earnings results on Tuesday, March 5th. The company reported ($0.69) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.77) by $0.08. The business had revenue of $2.84 million during the quarter, compared to the consensus estimate of $3.48 million. Equities research analysts expect that Dova Pharmaceuticals Inc will post -2.31 earnings per share for the current fiscal year.

Several research firms have recently commented on DOVA. JPMorgan Chase & Co. cut shares of Dova Pharmaceuticals from an “overweight” rating to an “underweight” rating and dropped their target price for the stock from $34.00 to $20.00 in a research report on Wednesday, January 23rd. LADENBURG THALM/SH SH raised their target price on shares of Dova Pharmaceuticals to $32.00 and gave the stock a “buy” rating in a research report on Tuesday, December 18th. They noted that the move was a valuation call. BidaskClub raised shares of Dova Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, March 21st. Finally, HC Wainwright began coverage on shares of Dova Pharmaceuticals in a research report on Thursday, December 20th. They issued a “buy” rating and a $18.00 target price for the company. One analyst has rated the stock with a sell rating, three have given a hold rating and five have issued a buy rating to the company. The company presently has a consensus rating of “Hold” and an average price target of $29.57.

In other Dova Pharmaceuticals news, Director Paul B. Manning purchased 68,000 shares of the firm’s stock in a transaction that occurred on Thursday, March 7th. The stock was bought at an average cost of $7.48 per share, for a total transaction of $508,640.00. The transaction was disclosed in a document filed with the SEC, which is available through this link. 60.30% of the stock is owned by company insiders.

ILLEGAL ACTIVITY WARNING: This report was first reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this report on another website, it was illegally copied and reposted in violation of US & international trademark and copyright laws. The original version of this report can be accessed at https://sportsperspectives.com/2019/04/02/pnc-financial-services-group-inc-has-38000-holdings-in-dova-pharmaceuticals-inc-dova.html.

Dova Pharmaceuticals Company Profile

Dova Pharmaceuticals, Inc, a pharmaceutical company, focuses on acquiring, developing, and commercializing drug candidates for thrombocytopenia disease. The company's lead drug candidate is avatrombopag that has completed Phase III clinical trials for the treatment of thrombocytopenia in patients with chronic liver disease.

Further Reading: What is the Rule of 72?

Want to see what other hedge funds are holding DOVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Dova Pharmaceuticals Inc (NASDAQ:DOVA).

Institutional Ownership by Quarter for Dova Pharmaceuticals (NASDAQ:DOVA)

Receive News & Ratings for Dova Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dova Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.